ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Prostate Related Issues
TRT is able to reduce prostate inflammation in men with BPH
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="Nelson Vergel" data-source="post: 101374" data-attributes="member: 3"><p>[ATTACH]4805[/ATTACH]</p><p></p><p>Rastrelli G, Cipriani S, Lotti F, et al. 186 - Testosterone replacement</p><p>therapy is able to reduce prostate inflammation in men with BPH, metabolic</p><p>syndrome and hypogonadism: Preliminary results from a randomized placebo</p><p>controlled clinical trial. European Urology Supplements 2018;17:e269.</p><p></p><p><a href="https://www.sciencedirect.com/science/article/pii/S1569905618310376" target="_blank">Testosterone replacement therapy is able to reduce prostate inflammation in men with BPH, metabolic syndrome and hypogonadism: Preliminary results from a randomized placebocontrolled clinical trial</a></p><p></p><p>Introduction & Objectives: BPH results from prostate tissue inflammation,</p><p>which frequently occurs in men with metabolic syndrome (MetS). MetS is often</p><p>associated with low testosterone (T). Recent evidence shows that low, rather</p><p>than high, T levels are associated with BPH/lower urinary tract symptoms</p><p>(LUTS).</p><p></p><p>The aim of the study was to evaluate if T replacement therapy (TRT) for 6</p><p>months in BPH men with MetS and low T, is able to improve LUTS and prostate</p><p>inflammation (as assessed by ultrasound and gene expression in prostate</p><p>tissue).</p><p></p><p>Materials & Methods: Ethical Committee approval has been obtained for the</p><p>trial. 120 men in the waiting list for BPH surgery and diagnosed with MetS</p><p>were enrolled in the clinical trial. Informed consent was obtained from each</p><p>patient. According to total T (TT) and calculated free T (cFT), they were</p><p>categorized into eugonadal (TT?12 nmol/L and cFT?225 pmol/L; n=48) and</p><p>hypogonadal men (TT<12 nmol/L and/or cFT<225 pmol/L; n=72).</p><p></p><p>Hypogonadal men were randomly assigned to receive T gel 2% (5 g/daily) or</p><p>placebo for 6 months. At baseline and follow-up visit (after 6 months), all</p><p>men filled out the International Prostatic Symptoms Score (IPSS) and</p><p>NIH-Chronic Prostatitis Symptom Index (NIH-CSPI) questionnaires and</p><p>underwent a trans-rectal prostate ultrasound. After surgery, prostate tissue</p><p>was collected.</p><p></p><p>Results: After adjusting for the baseline value, together with age, TT and</p><p>waist circumference, NIH-CSPI total score significantly decreased in both</p><p>the groups (p<0.001 vs. baseline), whereas IPSS total score did not change</p><p>in any of the groups. IPSS bother score significantly decreased only in</p><p>T-treated (p=0.042 vs. baseline value).</p><p></p><p>Although a significant increase in total prostate and adenoma volume</p><p>occurred in T-treated (both p<0.05 vs. the baseline value), T arm was</p><p>characterised by a significant decrease in ultrasound markers of prostate</p><p>inflammation, including arterial velocity and acceleration (both p<0.01 vs.</p><p>baseline value).</p><p></p><p>In a subset of patients (9 eugonadal, 11 placebo and 9 T-treated), the</p><p>expression by prostate tissue of inflammatory markers was evaluated. COX2,</p><p>MCP1 and RORC were found significantly decreased in T-treated as compared</p><p>with the placebo arm (all p<0.01) and for COX2 and MCP1 even in comparison</p><p>with eugonadal men (both p<0.05).</p><p></p><p>Conclusions: <strong>Six-month treatment with T gel 2% in hypogonadal men with BPH</strong></p><p><strong>and MetS is able to improve several clinical, ultrasound and molecular</strong></p><p><strong>proxies of prostate inflammation.</strong></p></blockquote><p></p>
[QUOTE="Nelson Vergel, post: 101374, member: 3"] [ATTACH alt="prostate bph.jpg"]4805[/ATTACH] Rastrelli G, Cipriani S, Lotti F, et al. 186 - Testosterone replacement therapy is able to reduce prostate inflammation in men with BPH, metabolic syndrome and hypogonadism: Preliminary results from a randomized placebo controlled clinical trial. European Urology Supplements 2018;17:e269. [URL="https://www.sciencedirect.com/science/article/pii/S1569905618310376"]Testosterone replacement therapy is able to reduce prostate inflammation in men with BPH, metabolic syndrome and hypogonadism: Preliminary results from a randomized placebocontrolled clinical trial[/URL] Introduction & Objectives: BPH results from prostate tissue inflammation, which frequently occurs in men with metabolic syndrome (MetS). MetS is often associated with low testosterone (T). Recent evidence shows that low, rather than high, T levels are associated with BPH/lower urinary tract symptoms (LUTS). The aim of the study was to evaluate if T replacement therapy (TRT) for 6 months in BPH men with MetS and low T, is able to improve LUTS and prostate inflammation (as assessed by ultrasound and gene expression in prostate tissue). Materials & Methods: Ethical Committee approval has been obtained for the trial. 120 men in the waiting list for BPH surgery and diagnosed with MetS were enrolled in the clinical trial. Informed consent was obtained from each patient. According to total T (TT) and calculated free T (cFT), they were categorized into eugonadal (TT?12 nmol/L and cFT?225 pmol/L; n=48) and hypogonadal men (TT<12 nmol/L and/or cFT<225 pmol/L; n=72). Hypogonadal men were randomly assigned to receive T gel 2% (5 g/daily) or placebo for 6 months. At baseline and follow-up visit (after 6 months), all men filled out the International Prostatic Symptoms Score (IPSS) and NIH-Chronic Prostatitis Symptom Index (NIH-CSPI) questionnaires and underwent a trans-rectal prostate ultrasound. After surgery, prostate tissue was collected. Results: After adjusting for the baseline value, together with age, TT and waist circumference, NIH-CSPI total score significantly decreased in both the groups (p<0.001 vs. baseline), whereas IPSS total score did not change in any of the groups. IPSS bother score significantly decreased only in T-treated (p=0.042 vs. baseline value). Although a significant increase in total prostate and adenoma volume occurred in T-treated (both p<0.05 vs. the baseline value), T arm was characterised by a significant decrease in ultrasound markers of prostate inflammation, including arterial velocity and acceleration (both p<0.01 vs. baseline value). In a subset of patients (9 eugonadal, 11 placebo and 9 T-treated), the expression by prostate tissue of inflammatory markers was evaluated. COX2, MCP1 and RORC were found significantly decreased in T-treated as compared with the placebo arm (all p<0.01) and for COX2 and MCP1 even in comparison with eugonadal men (both p<0.05). Conclusions: [B]Six-month treatment with T gel 2% in hypogonadal men with BPH and MetS is able to improve several clinical, ultrasound and molecular proxies of prostate inflammation.[/B] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Prostate Related Issues
TRT is able to reduce prostate inflammation in men with BPH
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top